Diseases of the Musculoskeletal System, Phase III

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)

Volunteers
Health Professionals

What is the purpose of this trial?

Brief Summary:

To evaluate the safety and tolerability of FG-3019 in subjects with IPF, and the efficacy of FG-3019 in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these subjects.

Trial with
Ra Pharmaceuticals, Inc.
Ages
40 years - 80 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Danielle Carlson

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Richard Nowak, MD, MS
Associate Professor of Neurology; Director, Program in Clinical & Translational Neuromuscular Research; Director, Yale Myasthenia Gravis Clinic

Sub-Investigator

Bhaskar Roy, MBBS, MHS

Last Updated
08/10/2023
Study HIC
#2000026786